GSK drops $10.6B on a cancer biotech — ride the biotech takeover wave
Pharmaceutical giant GSK just agreed to buy cancer-drug maker Nuvalent for $10.6 billion. This massive deal signals that big drug companies are in a spending mood to snap up innovative biotech firms.
Idea
When a massive acquisition like the GSK-Nuvalent deal happens, it shines a massive spotlight on the entire biotech sector. Big pharmaceutical companies are facing patent expirations on their current blockbuster drugs, meaning they desperately need to buy smaller companies with promising new treatments. This specific deal proves that the checkbooks are open and buyers are willing to pay massive premiums. Investors often rush into other biotech stocks after a major deal, hoping they will be the next to be acquired, which lifts the prices of biotech ETFs across the board.